Search

shutterstock_2261453831(1) (1)

Announcements

Announcements

HOMEWhat’s NewAnnouncements

2022.Mar.17

Subscription rights to the cash issue forfeited by directors of the Company reaching 50% and subscription being made available to specific persons

2022.Mar.17

Announcement of calls on unpaid shares of 2022 cash capital increase

2022.Feb.23

TFDA has granted the approval for the active cancer immunotherapy OBI-833 to proceed to a Phase II clinical trial

2022.Feb.23

Supplementary Statements On News Article

2022.Feb.22

Announcement of acquisition of preferred shares of Odeon Therapeutics (Cayman) Limited

2022.Feb.22

OBI Enters License Agreement with Odeon for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau

2022.Feb.15

OBI is invited to attend the“ QIC Healthcare Forum” (Investor meeting on air) held by QIC

2022.Feb.11

Announcement of issue price and banks designated to collect and deposit the proceeds

2022.Feb.09

The Active Cancer Immunotherapy OBI-822, has been granted by ANVISA of Brazil to proceed to Phase III Clinical Trial

2022.Feb.09

Supplementary statements on news article

News

Latest News

Events

Latest events